Esperion Therapeutis.Inc. buy StockNews.com
Summary
This prediction ended on 27.10.25 with a price of €2.29. The prediction had a final performance of 18.51%. StockNews_com has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. StockNews_com has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -17.061% | -17.061% | 59.782% |
| iShares Core DAX® | -6.016% | -4.595% | 1.274% |
| iShares Nasdaq 100 | 0.511% | 0.164% | 14.573% |
| iShares Nikkei 225® | -7.156% | -2.215% | 28.107% |
| iShares S&P 500 | -0.257% | -0.841% | 10.196% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
17.08.25
17.08.26
06.03.26
Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
05.10.24
05.10.25
06.10.25

